Jim Harris is the Co-founder and Chief Executive Officer of PolyCore Therapeutics LLC. Mr. Harris is a serial entrepreneur with 30+ years experience in the life sciences. His expertise is in business creation, commercialization and brand marketing. Mr. Harris is a former Merck executive (27+ years) most recently serving as Executive Director for Merck’s US Diversified Brands Franchise which he built, launched and led for the company. The franchise included 25 brands in nine therapeutic disease areas. He also serves as a commercial reviewer for the National Science Foundation and is a QED Business Advisor and steering committee member at the University City Science Center, located in Philadelphia. Mr. Harris received an MBA from California State University, Sacramento.
Sandhya Kortagere is the Inventor, Co-founder and Chief Scientific Officer of PolyCore Therapeutics LLC. Dr. Kortagere is a molecular pharmacologist with over 15 years experience in Drug Discovery and Development. She is currently an Associate Professor at Drexel University College of Medicine where she pioneered in the development of a platform technology called the Hybrid Structure Based method to design small molecule modulators to a variety of therapeutically relevant protein targets. Prior to her arrival at Drexel, she was a research and teaching specialist at Robert Wood Johnson Medical school of Rutgers University, NJ. Dr. Kortagere obtained her Ph.D at National Institute of Mental Health and Neurosciences, Bangalore, India in Molecular Pharmacology and pursued her postdoctoral fellowship at Mount Sinai Medical Center and Weill Cornell Medical College at NYC.
Michael Saporito is the Chief Operating Officer of PolyCore Therapeutics LLC. Dr. Saporito is an expert in Parkinson’s disease and has spent over 25 years in the biopharmaceutical industry studying neurological disorders. Dr. Saporito started his career at Cephalon Inc. where he established a research lab studying mechanisms of neurodegeneration in Parkinson’s disease, identified novel kinases involved in the neurodegenerative process in this disease and transitioned experimental drugs into clinical trials for the treatment of Parkinson’s disease. Dr. Saporito also headed the biology research group at Locus Pharmaceuticals and cofounded Melior Discovery where he was Chief Scientific Officer and a member of the board of directors. Dr. Saporito is a member of the Michael J. Fox Foundation review board and consults and advises venture capital groups and investment banks. Dr. Saporito is a graduate of Juniata College, obtained his Ph.D in Pharmacology at University of the Sciences in Philadelphia and continued his training as a postdoctoral fellow at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School in Neurology.
Advisors to the company include Dr. Jay Schneider, Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, who provides consultancy and expert advice on Parkinson’s disease in non-human primates; Alex Howarth – Financial; Dr. Heather Rose – Business Development; and University City Science Center’s Phase 1 Ventures accelerator program.
Your Name (required)
Your Email (required)